London, UK - Despite inducing only a modest drop in blood pressure (BP), the ACE inhibitor ramipril (Altace® - Monarch Pharmaceuticals) caused a significant reduction in cardiovascular death, MI, or ...

Preclinical and clinical data suggest that angiotensin-converting-enzyme inhibitors (ACEIs) may reduce the risk for ischemic events independent of the drugs' blood pressure-lowering effects. This is ...

Please provide your email address to receive an email when new articles are posted on . Patients with type 2 diabetes may have another therapeutic option to improve vascular dysfunction and markers of ...

Inhibition of angiotensin-converting enzyme (ACE) with ramipril as an adjunct to standard medical therapy increases both the maximum and the pain-free walking time of patients with peripheral artery ...

Angiotensin-converting-enzyme (ACE) inhibitors were developed for the treatment of hypertension. Subsequently they became indicated for several cardiovascular and renal conditions. ACE inhibitors play ...

Background: The Heart Outcomes Prevention Evaluation (HOPE), a Canadian-led, multicentre, randomized controlled trial, demonstrated the effectiveness of the ACE inhibitor ramipril in the secondary ...

People being prescribed ramipril could be at risk of suffering a serious kidney-related side effect that may need be monitored by a doctor. Ramipril is commonly prescribed to treat heart failure and ...